Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness
Name
nihms808576.pdf
Size
85.45 KB
Format
Adobe PDF
Checksum (MD5)
4af043b91a49a825584e9ae69d291932
Author(s)
Danziger, John
Lee, Joonwu
Mark, Roger G
Celi, Leo Anthony G.
Date Issued
November 2016
Journal
The Journal of Clinical Pharmacology
Publisher
Sage Publications
Citation
Lee, Joon et al. “Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness.” The Journal of Clinical Pharmacology 56, 12 (September 2016): 1500–1506 © 2016 The American College of Clinical Pharmacology
Version
Author's final manuscript
Abstract
Recent epidemiologic data linking proton pump inhibitor (PPI) use to acute and chronic kidney dysfunction is yet to be validated in other populations, and mechanisms have not been explored. Using a large, well phenotyped inception cohort of 15 063 critically ill patients, we examined the risk of acute kidney injury (AKI), as defined by the Kidney Disease Improving Global Outcomes criteria guidelines, according to prior use of a PPI, histamine-2 receptor antagonist (H 2 RA), or neither. A total of 3725 (24.7%) patients reported PPI use prior to admission, while 905 (6.0%) patients reported H 2 RA use. AKI occurred in 747 (20.0%) and 163 (18.0%) of PPI and H 2 RA users respectively, compared to 1712 (16.2%) of those not taking acid suppressive medications. In unadjusted analysis, PPI and H 2 RA users had a 28% (95%CI 1.17-1.41, P < .001) and 10% (95%CI 0.91-1.30, P =.31) higher risk of AKI compared to those taking neither class of medication. However, in sequential models that included adjustment for demographics, cardiovascular comorbidities, indications for PPI use, and severity of illness, the effect of PPI on the risk of AKI was attenuated, and in the adjusted analysis, PPI was not associated with AKI (OR 1.02; 95%CI 0.91-1.13, P =.73). The presence of sterile pyuria and hypomagnesemia did not modify the association between PPI use and AKI. In summary, after adjustment for demographics, illness severity, and the indication for PPI use, PPI use prior to admission is not associated with critical illness AKI.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/JCPH.805
